Dasolampanel

Drug Profile

Dasolampanel

Alternative Names: NGX-426

Latest Information Update: 11 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly; Horizon Pharma
  • Developer Raptor Pharmaceutical Corp
  • Class Analgesics; Antimigraines
  • Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 12 Aug 2014 Discontinued - Phase-I for Migraine in USA (PO)
  • 12 Aug 2014 Discontinued - Phase-I for Neuropathic pain in USA (PO)
  • 08 Nov 2010 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top